Selected References
Immunomodulators
Y. Azuma, K. Ohura (2004). Immunological modulation by lidocaine–epinephrine and
prilocaine–felypressin on the functions related to natural immunity in neutrophils and
macrophages. Curr. Drug Targ.: Immune, Endocr. Metabol. Disord. 4: 29–36.
S. Chada, R. Ramesh, A. M. Mhashilkar (2003). Cytokine- and chemokine-based gene therapy
for cancer. Curr. Op. Mol. Ther. 5: 463–474.
W. J. Fantl, S. Rosenberg (2000). Anti-angiogenesis as a therapeutic strategy for cancer. Ann.
Rep. Med. Chem. 35: 123.
M. Fischereder, M. Kretzler (2004). New immunosuppressive strategies in renal transplant recipients. J. Nephrol. 17: 9–18.
I. Krause, G. Valesini, R. Scrivo, Y. Shoenfeld (2003). Autoimmune aspects of cytokine and
anticytokine therapies. Am. J. Med. 115: 390–397.
E. C. Lavelle, P. McGuirk, K. H. G. Mills (2004). Molecules of infectious agents as immunomodulatory drugs. Curr. Top. Med. Chem. 4: 499–508.
S. H. Powis (1998). Lessons from an age-old war. Nature Medicine 4: 887–888.
M. J. Schultz, J. Kesecioglu, T. Van Der Poll (2004). Immunomodulating properties of
macrolides: animal and human studies. Curr. Med. Chem.: Anti-Inf. Ag. 3: 101–107.
J. S. Skotnicki, J. I. Levin (2003). TNF—a converting enzyme (TACE) as a therapeutic target.
Ann. Rep. Med. Chem. 38: 153.
B. K. Trivedi, J. E. Low, K. Carson, G. J. LaRosa (2000). Chemokines: Targets for novel therapeutics. Ann. Rep. Med. Chem. 35: 191.
A. O. Tzianabos (2000). Polysaccharide immunomodulators as therapeutic agents: structural
aspects and biologic function. Clin. Microbiol. Rev. 13: 523–533.
IMMUNOMODULATORS AND THEIR RECEPTORS
405
Immunomodulators
Y. Azuma, K. Ohura (2004). Immunological modulation by lidocaine–epinephrine and
prilocaine–felypressin on the functions related to natural immunity in neutrophils and
macrophages. Curr. Drug Targ.: Immune, Endocr. Metabol. Disord. 4: 29–36.
S. Chada, R. Ramesh, A. M. Mhashilkar (2003). Cytokine- and chemokine-based gene therapy
for cancer. Curr. Op. Mol. Ther. 5: 463–474.
W. J. Fantl, S. Rosenberg (2000). Anti-angiogenesis as a therapeutic strategy for cancer. Ann.
Rep. Med. Chem. 35: 123.
M. Fischereder, M. Kretzler (2004). New immunosuppressive strategies in renal transplant recipients. J. Nephrol. 17: 9–18.
I. Krause, G. Valesini, R. Scrivo, Y. Shoenfeld (2003). Autoimmune aspects of cytokine and
anticytokine therapies. Am. J. Med. 115: 390–397.
E. C. Lavelle, P. McGuirk, K. H. G. Mills (2004). Molecules of infectious agents as immunomodulatory drugs. Curr. Top. Med. Chem. 4: 499–508.
S. H. Powis (1998). Lessons from an age-old war. Nature Medicine 4: 887–888.
M. J. Schultz, J. Kesecioglu, T. Van Der Poll (2004). Immunomodulating properties of
macrolides: animal and human studies. Curr. Med. Chem.: Anti-Inf. Ag. 3: 101–107.
J. S. Skotnicki, J. I. Levin (2003). TNF—a converting enzyme (TACE) as a therapeutic target.
Ann. Rep. Med. Chem. 38: 153.
B. K. Trivedi, J. E. Low, K. Carson, G. J. LaRosa (2000). Chemokines: Targets for novel therapeutics. Ann. Rep. Med. Chem. 35: 191.
A. O. Tzianabos (2000). Polysaccharide immunomodulators as therapeutic agents: structural
aspects and biologic function. Clin. Microbiol. Rev. 13: 523–533.
IMMUNOMODULATORS AND THEIR RECEPTORS
405